Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2025-01-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份解除质押及再质押的公告
Regulatory Filings Classification · 100% confidence The document is an announcement regarding the release and re-pledging of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares involved, pledge dates, pledgees, and the impact on shareholding and company control. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledge status and related shareholder information. It does not fit into financial reports, earnings releases, or management reports. It is a typical regulatory filing about share pledges and shareholder disclosures, which falls under the category of Regulatory Filings (RNS). The document length is short and focused on a specific shareholder pledge event, confirming it is not a full report or presentation.
2025-01-10 Chinese
关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, the purpose of the pledge, and assurances about the absence of risks such as forced liquidation or impact on company control. The document includes tables with shareholding and pledge details and states that relevant registration and regulatory documents are available for inspection. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about a financing-related event (share pledge) by a major shareholder, not a full financial report or earnings release. It fits best under Capital/Financing Update (CAP) as it concerns financing activities related to share pledges by a controlling shareholder.
2024-12-30 Chinese
关于注销部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of certain special accounts for raised funds (募集资金专户) by Shenzhen BGI Genomics Co., Ltd. It details the background of the fundraising, the management and use of the funds, the decision to terminate a specific investment project, and the subsequent cancellation of the related fundraising accounts. The document includes specific dates of board meetings and shareholder meetings approving these actions, and it references prior announcements. The content is focused on capital management and changes related to fundraising accounts rather than financial results, audit opinions, or management discussions. The document length is 3375 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising activities and capital structure changes (specifically the cancellation of fundraising accounts and reallocation of funds).
2024-12-24 Chinese
关于注销部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of certain special accounts for raised funds (募集资金专户注销公告) by Shenzhen BGI Genomics Co., Ltd. It details the background of the fundraising, the management and use of the funds, and the specific accounts being closed after project completion and fund reallocation. The document includes references to regulatory approvals, board meetings, and shareholder meetings approving the use and cancellation of these accounts. It does not contain financial statements or detailed financial performance data, nor is it a report like an annual or interim report. The document is a formal announcement about the status and management of fundraising accounts, which fits the category of Capital/Financing Update (CAP) as it relates to fundraising activities and capital management updates.
2024-12-04 Chinese
关于参加2024年度深圳辖区上市公司集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company's participation in a 2024 investor interaction event organized by regulatory and stock exchange authorities. It mentions the event date, participation details, and the company's management who will attend. There is no financial data, no detailed report, no voting results, no legal or capital changes, and no certification. The document is under 5,000 characters and serves as a notice about an upcoming event rather than a report or transcript. Therefore, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous announcements that do not fit other specific categories.
2024-12-02 Chinese
关于部分董事、高级管理人员增持公司股份计划实施完成的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a share purchase plan by certain directors and senior management of the company. It details the number of shares acquired, the amounts spent, and confirms compliance with relevant securities laws and regulations. The document does not contain financial statements or financial performance data, nor is it a report or presentation. It is a disclosure of insider transactions related to directors and executives increasing their shareholdings. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 3487 characters, which is consistent with a detailed announcement but not a full financial report.
2024-11-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.